Jpmorgan Chase & CO Cytek Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 598,537 shares of CTKB stock, worth $3.67 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
598,537
Previous 608,440
1.63%
Holding current value
$3.67 Million
Previous $3.4 Million
2.36%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CTKB
# of Institutions
135Shares Held
72.2MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$72.2 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$58.2 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$40.8 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$25.5 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $825M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...